Low Dose Intravenous Immunoglobulin in Systemic Lupus Erythematosus: Analysis of 62 Cases

Yaniv Sherer MD1, Sabine Kuechler MD1, Juan Jose Scali MD2, Josef Rovensky MD3, Yair Levy MD4, Gisele Zandman-Goddard MD5 and Yehuda Shoenfeld MD1*

1 Department of Medicine B and Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
2 Jefe Unidad de Reumatologia Hospital Durand, Buenos Aires, Argentina
3 National Institute of Rheumatic Diseases, Piestany, Slovak Republic
4 Department of Medicine, Sapir Medical Center, Kfar Saba, Israel
5 Department of Medicine C, Wolfson Medical Center, Holon, and Sackler Faculty of Medicine, Tel Aviv University, Israel

Key words: low dose, intravenous immunoglobulin, systemic lupus erythematosus, thrombocytopenia, SLEDAI

Abstract

Background: Systemic lupus erythematosus is an autoimmune disease with diverse clinical manifestations that cannot always be regulated by steroids and immunosuppressive therapy. Intravenous immunoglobulin is an optional immunomodulatory agent for the treatment of SLE, but the appropriate indications for its use, duration of therapy and recommended dosage are yet to be established. In SLE patients, most publications report the utilization of a high dose (2 g/kg body weight) protocol. Objectives: To investigate whether lower doses of IVIg are beneficial for SLE patients. Methods: We retrospectively analyzed the medical records of 62 patients who received low dose IVIg (approximately 0.5 g/kg body weight).

Results: The treatment was associated with clinical improvement in many specific disease manifestations, along with a continuous decrease in SLEDAI scores (SLE Disease Activity Index). However, thrombocytopenia, alopecia and vasculitis did not improve following IVIg therapy.

Conclusions: Low dose IVIg is a possible therapeutic option in SLE and is associated with lower cost than the high dose regimen and possibly fewer adverse effects.

IMAJ 2008;10:55–57

Intravenous immunoglobulin therapy was originally utilized for the treatment of various immunodeficiency states [1]. To date, IVIg is a standard therapeutic modality for certain autoimmune diseases, including immune thrombocytopenic purpura, Kawasaki disease, Guillain-Barré syndrome and polymyositis, where it is used as an immunomodulatory agent [1]. IVIg is also occasionally used for the treatment of systemic lupus erythematosus, but for this indication it is still considered experimental and without any clear indications and methods of use [2,3]. Many case reports and case series (usually small) have described the beneficial effect of IVIg in SLE [4-14]. In general, IVIg therapy was well tolerated and resulted in better outcome, as measured by response of specific clinical manifestations and disease activity indexes, and it also had a steroid-sparing effect in some reports [14]. Most of the above-mentioned reports described a high dose protocol (2 g/kg body weight divided over 5 days), considered the immunomodulatory dose of IVIg. As IVIg therapy is expensive and is associated with adverse effects [15-18], we aimed to investigate whether lower doses of IVIg are beneficial for SLE patients. We analyzed the medical records of 62 SLE patients treated with low dose IVIg.

Patients and Methods

This retrospective study included a review of the medical records of 62 patients who were diagnosed as having SLE based on at least four American College of Rheumatology criteria [19]. All were treated with low dose IVIg for various indications at different time points. The demographic data collected for every patient included age, gender, age at diagnosis of SLE, and age at the commencement of IVIg therapy. The data recorded on IVIg therapy included: IVIg dosage in the first treatment course, IVIg dosage in the subsequent courses, the interval between treatment courses, and total number of courses. Response to treatment was evaluated by using both the response to single specific manifestations of the disease, as well as evaluation of the SLE disease activity index score at several time points.

Results

Of the 62 patients included in the study, 7 were men. The patients’ mean age at diagnosis was 33 ± 15 years and their mean age at the beginning of treatment was 40 ± 15 years. The dosage of IVIg used for the treatment of these SLE patients was variable but was approximately 0.5 g/kg body weight. IVIg dosage in the first course was 36 ± 18 g. IVIg dosage in the subsequent courses was 38 ± 42 g. The interval between treatment courses was 5 ± 2 weeks, and the number of treatment courses was 6 ± 6.

Regarding the clinical response to the treatment, Table 1 summarizes the precise rates of disappearance of specific clinical and laboratory manifestations of SLE. In general, mucosal ulcers,
The role of the appropriate IVIg dosage for use in SLE patients, the indications for IVIg and the recommended duration of therapy has not been established, probably due to the rarity of the disease. There are almost no controlled studies on IVIg therapy in lupus, and most are anecdotal or observational studies. In this retrospective study, including 62 cases of SLE patients treated with IVIg, it seems that IVIg at a dose close to 0.5 g/kg body weight per therapeutic course can also be effective in the majority of cases. Most clinical manifestations of the disease have shown a significant response to the IVIg infusion, and, most important, an improvement in SLEDAI score was noted months after initiation of IVIg administration. The use of low dose IVIg, which is about one-quarter of the regular dosage usually used for immunomodulation (2 g/kg body weight), is preferred in terms of both cost and adverse effects. Although IVIg is relatively safe, few complications may accompany its usage, the most frequent being rashes, headaches and arthralgias, as well as more rare conditions such as aseptic meningitis, renal failure and thrombosis [15,16,18]. Another issue is the appropriate IVIg dosage for the treatment of patients with autoimmune diseases in general, and lupus in particular. One study reported a better therapeutic effect in Kawasaki disease using a high dose (2 g/kg) of IVIg than with a low dose (1 g/kg) of IVIg therapy [25]. However, a conclusion from one disease cannot necessarily be applied to another.

In this study we observed several manifestations that failed to respond to IVIg therapy in SLE, including thrombocytopenia, alopecia and vasculitis. In addition, an important manifestation of the disease, proteinuria, disappeared in only a few cases. Therefore, while use of low dose IVIg in SLE seems to be beneficial as an add-on therapy, there are still many unanswered questions, such as the appropriate dosage to be used in certain clinical manifestations and the required duration of treatment. Additional research is required to clarify these issues, and they should include comparative studies of low dose and high dose IVIg as well as a comparison of IVIg with other therapeutic agents in SLE patients who have a similar disease. This large retrospec-

**Table 1. Response rate of specific disease manifestations of 62 SLE patients treated with low dose IVIg**

<table>
<thead>
<tr>
<th>Manifestation</th>
<th>Response rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucosal ulcers</td>
<td>100%</td>
</tr>
<tr>
<td>Fever</td>
<td>93%</td>
</tr>
<tr>
<td>Urinary casts</td>
<td>88%</td>
</tr>
<tr>
<td>New rash</td>
<td>75%</td>
</tr>
<tr>
<td>Pleurisy</td>
<td>71%</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>60%</td>
</tr>
<tr>
<td>Hematuria</td>
<td>57%</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>43%</td>
</tr>
<tr>
<td>Arthritis</td>
<td>30%</td>
</tr>
<tr>
<td>Low complement levels</td>
<td>27%</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>20%</td>
</tr>
<tr>
<td>Headache</td>
<td>17%</td>
</tr>
</tbody>
</table>

Percentages represent patients in whom the abnormal clinical/laboratory abnormality completely resolved.

**Figure 1.** SLEDAI scores of 62 SLE patients treated with low dose IVIg before and at three different time points after the treatment.

SLEDAI = SLE Disease Activity Index

fever, urinary casts, new rash, hematuria, pericarditis and pleurisy resolved in more than 50% of the affected patients, along with disappearance of seizures and psychosis in two patients. On the other hand, leukopenia, arthritis, low complement levels, proteinuria and headache resolved in less than 50% of the affected patients. A few clinical manifestations did not improve at all following low dose IVIg: namely, thrombocytopenia (4 patients), vasculitis (6 patients) and alopecia (3 patients). A comparison of SLEDAI scores before low dose IVIg therapy and at three different time points after IVIg administration (up to 8 months following therapy) disclosed a significant and continuous decline in the scores from 15 ± 7.8 to 5.2 ± 5.7 [Figure 1].

**Discussion**

IVIg has been widely reported as a possible immunomodulatory agent for SLE [4-14], mainly for severe cases in which it was considered as a salvage immunotherapeutic agent, but also as an add-on therapy for the disease. We previously reported that IVIg can reduce disease activity and daily prednisone dosages among SLE patients, as well as the autoantibodies associated with lupus [11]. Moreover, IVIg can also effectively ameliorate lupus nephritis in some cases [10], and has been reported to be as effective as cyclophosphamide in maintenance of lupus nephritis remission over 18 months [20]. The mechanisms of action of IVIg in autoimmune diseases are diverse and include all arms of the immune system. Anti-idiotypic antibodies within IVIg directed towards pathogenic idiotypes that are found over autoantibodies are also implicated in these mechanisms of action of IVIg [21,22]. Accordingly, it has been demonstrated that IVIg preparations enriched with anti-idiotypes against anti-dsDNA antibodies are much more effective in amelioration of experimental SLE compared to regular IVIg preparations [21]. Two recently reported mechanisms of action of IVIg include presence of anti-BAFF antibodies within IVIg preparations, and greater activity of T regulatory cells following IVIg infusion [23,24].
References


Acknowledgments. This study was supported in part by the Fed-erico Foundation, Zurich, Switzerland (to Y. Sherer and Y. Shoen-feld).

Antibiotics in common respiratory tract infections

To what extent do antibiotics reduce the risk of serious complications after common respiratory tract infections? Petersen et al. found that serious complications were rare after upper respiratory tract infections, sore throat, and otitis media, and the number needed to treat was over 4000. The risk of pneumonia after chest infection was high, particularly in elderly people, and was substantially reduced by antibiotic use, with a number needed to treat of 39 for those aged 65 and 96–119 in younger age groups. The authors conclude that antibiotics are not justified to reduce the risk of serious complications for upper respiratory tract infection, sore throat, or otitis media, but that antibiotics substantially reduce the risk of pneumonia after chest infection, particularly in elderly people in whom the risk is highest.

Correspondence: Dr. Y. Shoenfeld, Dept. of Medicine B, Sheba Medical Center, Tel Hashomer 52621, Israel.
Phone: (972-3) 530-2652
Fax: (972-3) 535-2855
email: shoenfel@post.tau.ac.il